ECML Euclidean Fundamental Value ETF

Expense Ratio
0.95%
Dividend
1.22%
Previous close
$37.65
Est. 12 months change
+15.12%
Projected Price
$43.34

Profitability Metrics

Return on Equity (ROE)
19.04%
Return on Assets (ROA)
8.52%
Return on Invested Capital (ROIC)
18.38%
Weighted Average Cost of Capital (WACC)
8.02%
ROIC - WACC
10.36%
Updated : 2026-05-20 18:38 ET

Valuation Metrics

P/E Ratio
12.06
Forward P/E
11.74
PEG Ratio
1.90
Debt Current Ratio
2.99

Growth & Cash Flow

Gross Margin
37.27%
Operating Margin
14.89%
FCF Margin
13.80%
TTM Revenue Growth
6.74%
Projected 12M EPS Growth
2.69%

Price Change

Price % from 50 SMA
1.78%
Price % from 200 SMA
8.31%
6 Months
18.41%
1 Year
21.31%
2 Years
12.98%
The above metrics represent weighted averages, calculated using each stock's individual value weighted by its proportion of ETF holdings.

Top 10 Holdings

Stock TickerWeight
PLAB3.13%
MLI3.07%
FOXA2.31%
MATX2.31%
FCX2.27%
HUM2.26%
CF2.21%
BWA2.21%
ALSN2.18%
PRDO2.18%

ETF Analysis

Fund Overview

Euclidean Fundamental Value ETF (ECML) currently reports 62 stock positions (subject to change), placing it in the selectively diversified range by holdings breadth. The top line-up is PLAB (3.13%), MLI (3.07%), FOXA (2.31%), with PLAB as the largest single weight at 3.13%. Together, the top three holdings account for 8.51%, which points to a relatively flat weight distribution where no single cluster of names dominates outcomes. The weight distribution suggests a portfolio designed to capture thematic upside while avoiding excessive dependence on any single name outside the largest positions.

Profitability & Capital Efficiency

Assessing the quality of returns on invested capital, ROIC is 18.38%, WACC is 8.02%, and the economic spread is 10.36%. On balance, the portfolio's businesses are clearing their capital cost hurdle with room to spare. Supporting metrics show ROE at 19.04% and ROA at 8.52%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a portfolio with credible compounding capacity if current operating execution persists.

Valuation

The portfolio's current market valuation reflects trailing P/E of 12.06, forward P/E of 11.74, PEG of 1.90. The trailing-to-forward compression is minimal, consistent with a market that sees limited earnings acceleration from current levels. The PEG reads as moderate — investors are paying a fair but not discounted price for the growth embedded in current estimates. At 2.99, the aggregate current ratio reflects strong balance sheet liquidity across the portfolio. Across multiples and liquidity, the portfolio is priced in a way that reflects current expectations reasonably well — leaving limited room for error, but also limited near-term downside from valuation compression alone.

Margins & Cash Generation

Looking at margins from gross to free cash flow, gross margin sits at 37.27%, operating margin at 14.89%, and free cash flow margin at 13.80%. The gross margin reading is middling — acceptable, but leaving less room for error at the production level. Modest operating margins indicate that while revenues are being generated, converting them to earnings is less efficient. The portfolio's cash conversion is middle-of-the-road — sufficient for operational needs, but leaving limited surplus for discretionary allocation. Together, these margins describe a portfolio where business quality varies — and where macro or sector headwinds could disproportionately impact the weaker-margin holdings.

Growth & Forward Outlook

Projected 12-month EPS growth of 2.7% is a constructive signal — measured earnings expansion supports the forward valuation case without relying on aggressive extrapolation. Turning to growth and analyst expectations, TTM revenue growth of 6.74% pointing to stable operational progress without outsized acceleration, while the estimated 12-month price change of 15.27%, where target prices point to mid-range appreciation potential from current levels. The distinction matters: revenue growth tells you what the businesses are doing, price targets tell you what analysts think the market will pay for it. Ultimately, the alignment between revenue momentum and analyst targets will depend on execution quality and the broader rate and sentiment environment. The estimated 12-month price change is a weighted composite of analyst price target estimates adjusted by each holding's ETF weight, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

Conclusion

Buy

Taken together, the metrics present a favorable setup — not without risk, but with enough quality and momentum to support a positive view.

This assessment reflects quantitative metrics only and does not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results.